Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCBHA Hematologic Genetic Testing Coverage | OpenPa…
    Ask Trek AI about this page
    ModifiedCarolina Behavioral Health Alliance (CBHA)Policy N/A

    CONCERT GENETIC TESTING: HEMATOLOGIC CONDITIONS (NONCANCEROUS)

    Customize your policy alerts

    Sign up for all carolinabehavioralhealth policy alerts

    Know when carolinabehavioralhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity criteria for genetic testing to confirm or establish diagnoses of inherited thrombophilia, hemoglobinopathies, hemophilia A or B, von Willebrand disease, and other noncancerous hematologic conditions.

    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyCONCERT GENETIC TESTING: HEMATOLOGIC CONDITIONS (NONCANCEROUS)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument qualifying bleeding manifestations or, when applicable, normal platelet count, prolonged aPTT, and normal PT for hemophilia testing.
    SourceLink
    POLICY UPDATE CHANGES

    The policy revision updated the coding, reference table, background, and references.

    The policy revision removed F8 Sequencing Analysis from the hemophilia policy reference table.

    The V1.2025 revision updated the G6PD, hemophilia, von Willebrand disease, inherited thrombophilia, and hemoglobinopathy sections and references.

    Criteria for known familial variant analysis in noncancerous hematologic conditions were moved to the general genetic and molecular testing policy.

    The policy title was updated to reflect the V1.2025 version during the November 2024 semi-annual review.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Condition-specific clinical criteria sections
    2Inherited thrombophilia variants evaluated
    2Hemophilia types addressed
    2Tests explicitly considered investigational
    8Named noncancerous hematologic conditions potentially covered
    V1.2025Current policy version

    Condition-Specific Coverage Criteria

    Inherited Thrombophilia — F5 and F2 Variant Analysis

    F5 and F2 variant analysis is medically necessary when at least one qualifying pathway is met.

    Qualifying inherited-thrombophilia pathway

    • VTE with qualifying provocation: The member/enrollee had venous thromboembolism (VTE) provoked by a nonsurgical major transient risk factor, pregnancy or postpartum, or combination oral contraceptive use.
    • Anticoagulation discontinuation with unusual-site thrombosis: The member/enrollee is planning to discontinue anticoagulation after VTE and has a history of cerebral venous thrombosis or splanchnic venous thrombosis.
    • Minor provoking risk factor with family history: The member/enrollee has a minor provoking risk factor for VTE, such as immobility, minor injury, illness, or infection, and either has two first- or second-degree relatives with VTE or has a relative with VTE under age 50 whose thrombophilia status is unknown.
    • Female planning pregnancy with high-risk familial variant: The member/enrollee is female, is planning a pregnancy, and has a first- or second-degree relative known to be homozygous for factor V Leiden or known to be a compound heterozygote for factor V Leiden and the prothrombin F2 mutation.
    • Systemic cancer treatment with family history: The member/enrollee is receiving systemic cancer treatment, does not have a personal history of VTE, and has a first-degree relative with VTE.

    Hemoglobinopathies — HBA1/HBA2 and HBB Analysis

    HBA1/HBA2 and/or HBB variant analysis is medically necessary when the screening pathway is met.

    Qualifying hemoglobinopathy screening: The member/enrollee’s hematologic screening results are positive for a hemoglobinopathy, or the results do not conclusively diagnose or rule out a hemoglobinopathy.

    Screening may include MCV, MCH, CBC, hemoglobin electrophoresis, or dichlorophenol indophenol (DCIP).

    Hemophilia A and B — F8 and F9 Analysis

    F8 and/or F9 variant analysis is medically necessary when either the clinical-feature pathway or the laboratory pathway is met.

    Qualifying hemophilia findings

    • Clinical features: Hemarthrosis; deep-muscle hematomas; intracranial bleeding without major trauma; neonatal cephalohematoma or intracranial bleeding; prolonged oozing, renewed, prolonged, or delayed bleeding after tooth extraction, mouth injury, circumcision, surgery, or trauma; poor wound healing after surgery or trauma; unexplained gastrointestinal bleeding or hematuria; heavy or prolonged menstrual bleeding; prolonged, recurrent, bilateral nosebleeds; or excessive bruising, especially with firm subcutaneous hematomas.>= 1 feature
    • Laboratory features: Normal platelet count, prolonged activated partial thromboplastin time (aPTT), and normal prothrombin time (PT).All 3 laboratory findings

    Von Willebrand Disease — VWF Variant Analysis

    VWF variant analysis is not medically necessary under this policy.

    Investigational testing: VWF variant analysis to confirm or establish a diagnosis of von Willebrand disease is considered investigational because the diagnosis can be achieved by standard laboratory and biochemical testing.

    Other Covered Hematologic Conditions

    Genetic testing is medically necessary when the member demonstrates clinical features consistent with the disorder and testing will establish or confirm the diagnosis to guide management.

    Other covered noncancerous hematologic conditions

    • Listed conditions: Atypical hemolytic-uremic syndrome; complete plasminogen activator inhibitor 1 deficiency; Diamond-Blackfan anemia; hereditary spherocytosis; Factor VII deficiency; Factor X deficiency; Factor XI deficiency (Hemophilia C); Factor XII deficiency; or Factor XIII deficiency.
    • Other noncancerous hematologic conditions: All other noncancerous hematologic conditions not specifically discussed in this or another medical policy are evaluated under the General Approach to Genetic and Molecular Testing.

      Clinical features may be identified in GeneReviews, OMIM, the National Library of Medicine, Genetics Home Reference, or another scholarly source.

    Investigational Testing

    The following testing is not covered as medically necessary and is considered investigational.

    Investigational diagnostic variant analysis: VWF variant analysis to confirm or establish von Willebrand disease, or G6PD variant analysis to confirm or establish G6PD deficiency, is considered investigational.

    Von Willebrand disease can be diagnosed by standard laboratory and biochemical testing; G6PD deficiency can be diagnosed by quantitative spectrophotometric analysis or a rapid fluorescent spot test.

    F5/F2 variant analysis is investigational when ordered for fetal loss or adverse pregnancy outcomes, including placental abruption, fetal growth restriction, or preeclampsia.

    VWF variant analysis to confirm or establish von Willebrand disease is not medically necessary under this policy.

    VWF variant analysis for diagnosis is considered investigational because von Willebrand disease can be diagnosed using standard laboratory and biochemical testing.

    G6PD variant analysis for diagnosis is considered investigational. G6PD deficiency can be evaluated with quantitative spectrophotometric analysis or a rapid fluorescent spot test.

    F5/F2 variant analysis is investigational for inherited-thrombophilia indications other than the specified medically necessary pathways in this policy.

    HBA1/HBA2 and/or HBB analysis is investigational when ordered for indications other than confirming or establishing alpha-thalassemia, beta-thalassemia, or sickle cell disease after positive or inconclusive hematologic screening.

    F8 and/or F9 analysis is investigational for indications other than confirming or establishing hemophilia A or B in a member/enrollee with qualifying bleeding manifestations or the specified laboratory findings.

    Coding Reference

    Covered CPT CodesCPTCovered
    81241Factor V (Leiden) Mutation Analysis
    81240Prothrombin (Factor II) 20210G>A Mutation Analysis
    ICD-10 CodesICD-10
    D68.51Factor V Leiden mutation
    D68.2Hereditary deficiency of other clotting factors
    D68.59Other thrombophilia
    R79.1Abnormal coagulation profile
    Z86.2Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
    I82.90Embolism and thrombosis of unspecified vein
    D68.52Prothrombin gene mutation
    Covered CPT CodesCPTCovered
    81257HBA1/HBA2 variant analysis
    81259HBA1/HBA2 variant analysis
    81269HBA1/HBA2 variant analysis
    81363HBB variant analysis
    81364HBB variant analysis
    ICD-10 CodesICD-10
    D56.0Alpha thalassemia
    D56.9Thalassemia, unspecified
    D53.9Nutritional anemia, unspecified
    R70.1Abnormality of red blood cells
    D56.3Thalassemia trait
    D56.8Other thalassemias
    Z86.2Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
    D57Sickle-cell disorders
    D56.1Beta thalassemia
    D64.9Anemia, unspecified
    Covered CPT CodesCPTCovered
    81403Factor VIII (F8) variant analysis
    81406Factor VIII (F8) variant analysis
    81407Factor VIII (F8) variant analysis
    81238Factor IX (F9) variant analysis
    81479Factor IX (F9) variant analysis
    ICD-10 CodesICD-10
    D66Hereditary factor VIII deficiency
    D67Hereditary factor IX deficiency
    I62.9Nontraumatic intracranial hemorrhage, unspecified
    M25Other joint disorders
    N92.2Excessive menstruation at puberty
    R04.0Epistaxis
    R31Hematuria
    CPT CodesCPT
    81247G6PD variant analysis
    81248G6PD variant analysis
    81249G6PD variant analysis
    81479G6PD variant analysis
    ICD-10 CodesICD-10
    D55.0Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency
    Experimental CPT CodesCPTExperimental
    81408VWF variant analysis
    81479VWF variant analysis
    ICD-10 CodesICD-10
    D68.0Von Willebrand's disease
    CPT CodesCPT
    81400Other covered hematologic conditions, noncancerous
    81401Other covered hematologic conditions, noncancerous
    81402Other covered hematologic conditions, noncancerous
    81403Other covered hematologic conditions, noncancerous
    81404Other covered hematologic conditions, noncancerous
    81405Other covered hematologic conditions, noncancerous
    81406Other covered hematologic conditions, noncancerous
    81407Other covered hematologic conditions, noncancerous
    81408Other covered hematologic conditions, noncancerous
    Experimental CPT CodesCPTExperimental
    81408VWF variant analysis
    81479VWF variant analysis
    Experimental CPT CodesCPTExperimental
    81247G6PD variant analysis
    81248G6PD variant analysis
    81249G6PD variant analysis
    81479G6PD variant analysis
    Hospital bed confinement for acute illness
    Minimum durationAt least 3 days
    SettingConfinement to bed in a hospital
    Clinical contextAcute illness; this is a nonsurgical transient risk factor
    Bed confinement outside hospital
    Minimum duration

    Documentation and Provider Actions

    Documentation Required

    Inherited Thrombophilia: Document Qualifying History

    Document the member/enrollee’s qualifying clinical history and family history before billing F5 (81241) and/or F2 (81240) variant analysis to confirm or establish inherited thrombophilia. Testing is medically necessary only when at least one qualifying pathway below is met.

    • Venous thromboembolism (VTE) provoked by a nonsurgical major transient risk factor, pregnancy or postpartum, or combination oral contraceptive use.
    • The member/enrollee is planning to discontinue anticoagulation after VTE and has a history of cerebral venous thrombosis or splanchnic venous thrombosis.
    • VTE with a minor provoking risk factor (such as immobility, minor injury, illness, or infection) plus either two first- or second-degree relatives with VTE, or one relative with VTE under age 50 whose thrombophilia status is unknown.
    • A female member/enrollee planning pregnancy who has a first- or second-degree relative known to be homozygous for factor V Leiden, or known to be a compound heterozygote for factor V Leiden and the prothrombin (F2) mutation.
    • Systemic cancer treatment, no personal history of VTE, and a first-degree relative with VTE.
    • Retain the clinical and family-history documentation supporting the applicable pathway in the medical record.

    Clinical Background

    Genetic testing for noncancerous hematologic conditions may confirm a suspected diagnosis in a symptomatic member/enrollee, alter management, and reduce the need for additional diagnostic workup. This policy addresses inherited thrombophilia, hemoglobinopathies, hemophilia A or B, von Willebrand disease, G6PD deficiency, and other inherited hematologic conditions with known genetic associations. Testing is generally supported when clinical features are consistent with the disorder and the result will guide management; some diagnoses can instead be established through standard laboratory or biochemical testing.

    Key Definitions

    Von Willebrand disease diagnosis
    DiagnosisVon Willebrand disease
    Diagnostic approachDiagnosis can be achieved by standard laboratory testing
    Additional testing contextBiochemical testing can also establish the diagnosis
    VTE
    AbbreviationVTE
    Full termVenous thromboembolism
    Policy contextVTE is used in the inherited-thrombophilia criteria

    Covered Genetic Testing Indications

    F5 and F2 Variant Analysis to Confirm or Establish Inherited Thrombophilia

    F5 and F2 variant analysis is covered to confirm or establish inherited thrombophilia when at least one qualifying pathway is met.

    Qualifying inherited-thrombophilia pathway

    • VTE with qualifying provocation: The member/enrollee had VTE provoked by a nonsurgical major transient risk factor, pregnancy or postpartum, or combination oral contraceptive use.
    • Anticoagulation discontinuation with unusual-site thrombosis: The member/enrollee is planning to discontinue anticoagulation after VTE and has a history of cerebral venous thrombosis or splanchnic venous thrombosis.
    • Minor provoking risk factor with family history: The member/enrollee has a minor provoking risk factor for VTE and either has two first- or second-degree relatives with VTE or has a relative with VTE under age 50 whose thrombophilia status is unknown.

    Eligibility Requirements

    For VTE associated with a minor provoking risk factor, F5/F2 testing requires either two first- or second-degree relatives with VTE or one relative with VTE who was younger than age 50 and whose thrombophilia status is unknown. Minor provoking factors may include immobility, minor injury, illness, or infection. Nonsurgical transient risk factors may include hospital bed confinement for at least 3 days, bed confinement outside the hospital for at least 3 days, or a leg injury with decreased mobility for at least 3 days.

    HBA1/HBA2 and/or HBB testing requires hematologic screening that is positive for a hemoglobinopathy or that does not conclusively diagnose or rule one out. Relevant screening may include MCV, MCH, CBC, hemoglobin electrophoresis, or DCIP.

    Investigational and Noncovered Indications

    The following indications are not covered as medically necessary and are considered investigational: F5/F2 testing for fetal loss or adverse pregnancy outcomes; HBA1/HBA2 and/or HBB testing without positive or inconclusive hemoglobinopathy screening; F8/F9 testing without qualifying hemophilia clinical or laboratory findings; VWF variant analysis to diagnose von Willebrand disease; and G6PD variant analysis to diagnose G6PD deficiency.

    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyCONCERT GENETIC TESTING: HEMATOLOGIC CONDITIONS (NONCANCEROUS)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument qualifying bleeding manifestations or, when applicable, normal platelet count, prolonged aPTT, and normal PT for hemophilia testing.
    SourceLink
    On This Page
    Condition-Specific Coverage CriteriaCoding ReferenceDocumentation and Provider ActionsClinical BackgroundKey DefinitionsCovered Genetic Testing IndicationsEligibility RequirementsInvestigational and Noncovered Indications
    At least 3 days
    SettingConfinement to bed outside of the hospital
    Risk-factor categoryMinor transient risk factor
    Leg injury with decreased mobility
    Minimum durationAt least 3 days
    Injury typeLeg injury
    Associated findingDecreased mobility
    Documentation Required

    Hemoglobinopathy: Document Screening Results

    Document the member/enrollee’s hematologic screening results before HBA1/HBA2 and/or HBB variant analysis. Testing is medically necessary when screening is positive for a hemoglobinopathy or does not conclusively diagnose or rule one out.

    • Record relevant results, including MCV, MCH, CBC, hemoglobin electrophoresis, and/or dichlorophenol indophenol (DCIP) testing.
    • The testing is used to confirm or establish alpha-thalassemia, beta-thalassemia, or sickle cell disease.
    • Include the actual screening findings and explain why results are positive, inconclusive, or insufficient to rule out hemoglobinopathy.
    • Applicable testing includes HBA1/HBA2 variant analysis (81257, 81259, 81269) and/or HBB variant analysis (81363, 81364).
    Documentation Required

    Hemophilia: Document Bleeding and Laboratory Findings

    Document the clinical and laboratory findings supporting F8 and/or F9 variant analysis to confirm or establish hemophilia A or B. Medical necessity requires qualifying bleeding features and the specified laboratory pattern.

    • Clinical features may include hemarthrosis, especially with mild or no antecedent trauma; deep-muscle hematomas; intracranial bleeding without major trauma; neonatal cephalohematoma or intracranial bleeding; prolonged oozing or renewed bleeding after tooth extraction, mouth injury, or circumcision; prolonged or delayed bleeding or poor wound healing after surgery or trauma; unexplained gastrointestinal bleeding or hematuria; heavy or prolonged menstrual bleeding, especially from menarche; prolonged, recurrent, or bilateral nosebleeds; or excessive bruising, especially firm subcutaneous hematomas.
    • Laboratory findings must include a normal platelet count, prolonged activated partial thromboplastin time (aPTT), and normal prothrombin time (PT).
    • Applicable testing includes F8 variant analysis (81403, 81406, 81407) and/or F9 variant analysis (81238; 81479 where applicable).
    • Retain the bleeding history and laboratory reports in the medical record.
    Denial Risk

    Inherited Thrombophilia: Nonqualifying Indications

    F5 (81241) and F2 (81240) variant analysis is investigational for indications outside the defined inherited-thrombophilia criteria and may be denied. Do not submit testing solely for fetal loss or adverse pregnancy outcomes without a qualifying indication.

    • Nonqualifying examples include fetal loss, placental abruption, fetal growth restriction, and preeclampsia.
    • Verify that the record supports a covered VTE history, qualifying anticoagulation-discontinuation plan, qualifying minor-risk-factor and family-history pathway, qualifying pregnancy-planning family history, or qualifying systemic-cancer-treatment pathway.
    Denial Risk

    Hemoglobinopathy: Other Indications

    HBA1/HBA2 and HBB variant analysis is investigational for all indications other than confirming or establishing alpha-thalassemia, beta-thalassemia, or sickle cell disease when hematologic screening is positive or inconclusive. Claims lacking qualifying screening documentation may be denied.

    • Do not use this testing for indications unrelated to a suspected hemoglobinopathy.
    • Ensure the record includes MCV, MCH, CBC, hemoglobin electrophoresis, DCIP, or other relevant screening results and explains why molecular testing is needed.
    • Applicable codes are HBA1/HBA2 81257, 81259, 81269 and HBB 81363, 81364.
    Denial Risk

    Hemophilia: Other Indications

    F8 and/or F9 variant analysis is investigational for all indications other than confirming or establishing hemophilia A or B when the member/enrollee has qualifying clinical features and the required laboratory findings. Claims without both supporting bleeding history and laboratory documentation may be denied.

    • Applicable F8 codes: 81403, 81406, and 81407.
    • Applicable F9 codes: 81238 and 81479.
    • Do not submit testing for nonspecific symptoms or abnormal findings that do not establish the required hemophilia-related clinical and laboratory pattern.
    Note

    VWF Variant Analysis: Provider Action

    VWF variant analysis is investigational for confirming or establishing a diagnosis of von Willebrand disease. Providers should use standard laboratory and biochemical testing to evaluate the diagnosis rather than relying on molecular testing.

    • Applicable codes include 81408 and 81479.
    • Document the clinical rationale and prior standard diagnostic evaluation when molecular testing is considered.
    Denial Risk

    Von Willebrand Disease: Investigational Testing

    VWF variant analysis (81408, 81479) to confirm or establish a diagnosis of von Willebrand disease is investigational and may be denied. Von Willebrand disease can be diagnosed through standard laboratory and biochemical testing.

    • Use standard laboratory and biochemical testing as the primary diagnostic approach.
    • Do not represent VWF variant analysis as medically necessary solely to diagnose von Willebrand disease.
    Denial Risk

    G6PD Variant Analysis: Investigational

    G6PD variant analysis is investigational and may be denied when used to confirm or establish glucose-6-phosphate dehydrogenase deficiency. Providers should use established biochemical testing to make the diagnosis.

    • Applicable codes include 81247, 81248, 81249, and 81479.
    • Diagnosis can be established by quantitative spectrophotometric analysis or, more commonly, a rapid fluorescent spot test detecting NADPH generation from NADP.
    • Document the results of standard testing and the reason molecular testing is being considered.
    Denial Risk

    Insufficient Clinical Features: Medical-Necessity Risk

    For genetic testing of other noncancerous hematologic conditions, document clinical features consistent with the suspected disorder. Insufficient or nonspecific clinical information creates a medical-necessity failure and denial risk.

    • Testing to establish or confirm aHUS, complete plasminogen activator inhibitor 1 deficiency (PAI-1), Diamond-Blackfan anemia, hereditary spherocytosis, factor VII deficiency, factor X deficiency, factor XI deficiency (hemophilia C), factor XII deficiency, or factor XIII deficiency is medically necessary only when clinical features are consistent with the disorder and testing will guide management.
    • The listed conditions are not comprehensive; use authoritative resources such as GeneReviews, OMIM, the National Library of Medicine, Genetics Home Reference, or other scholarly sources to support disorder-specific clinical features.
    • Testing for other noncancerous hematologic conditions not specifically addressed in this or another policy is evaluated under the General Approach to Genetic and Molecular Testing criteria.
    • Record the relevant symptoms, examination findings, laboratory abnormalities, family history, and management impact; do not submit testing when clinical features are absent or insufficient.
    Documentation Required

    Thalassemia: Genetic Counseling and Reproductive Planning

    For suspected thalassemia, document the provider actions that connect genetic testing to care planning. The record should show genetic counseling, individualized reproductive risk assessment, and the member/enrollee’s prenatal or preimplantation planning when applicable.

    • Provide or arrange genetic counseling regarding the suspected alpha- or beta-thalassemia diagnosis, inheritance pattern, and implications for family members.
    • Calculate and document reproductive risk using the member/enrollee’s results and the relevant partner or family history, including evaluation of the partner when appropriate.
    • Document counseling and planning for prenatal diagnosis and/or preimplantation genetic testing when the member/enrollee is considering pregnancy or assisted reproduction.
    • Link the test result to a documented management, reproductive, or family-planning decision.
    Close relatives
    DefinitionBlood relatives on the same side of the family
    First-degree relativesParents, siblings, and children
    Second-degree relativesGrandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings
    Third-degree relativesGreat grandparents, great aunts, great uncles, great grandchildren, and first cousins
    Nonsurgical transient risk factors
    Hospital acute illnessConfinement to bed in the hospital with acute illness for at least 3 days
    Acute-illness admissionAdmission of less than 3 days with acute illness may be part of a combination of minor transient risk factors
    Other minor transient factorsConfinement to bed outside the hospital for at least 3 days, or a leg injury associated with decreased mobility for at least 3 days
  1. Female planning pregnancy with high-risk familial variant: The member/enrollee is female, is planning a pregnancy, and has a first- or second-degree relative known to be homozygous for factor V Leiden or known to be a compound heterozygote for factor V Leiden and the prothrombin F2 mutation.
  2. Systemic cancer treatment with family history: The member/enrollee is receiving systemic cancer treatment, does not have a personal history of VTE, and has a first-degree relative with VTE.
  3. HBA1/HBA2 and/or HBB Analysis for Hemoglobinopathies

    HBA1/HBA2 and/or HBB analysis is covered to confirm or establish alpha-thalassemia, beta-thalassemia, or sickle cell disease when hematologic screening is positive or inconclusive.

    Qualifying hemoglobinopathy screening: The member/enrollee’s hematologic screening results are positive for a hemoglobinopathy, or the results do not conclusively diagnose or rule out a hemoglobinopathy.

    Screening may include MCV, MCH, CBC, hemoglobin electrophoresis, or DCIP.

    F8 and/or F9 Analysis to Confirm or Establish Hemophilia A or B

    F8 and/or F9 analysis is covered to confirm or establish hemophilia A or B when the clinical or laboratory pathway is met.

    Qualifying hemophilia findings

    • Clinical features: Hemarthrosis; deep-muscle hematomas; intracranial bleeding without major trauma; neonatal cephalohematoma or intracranial bleeding; prolonged or renewed bleeding after tooth extraction, mouth injury, or circumcision; prolonged or delayed bleeding or poor wound healing after surgery or trauma; unexplained gastrointestinal bleeding or hematuria; heavy or prolonged menstrual bleeding; prolonged recurrent bilateral nosebleeds; or excessive bruising with firm subcutaneous hematomas.>= 1 feature
    • Laboratory features: Normal platelet count, prolonged activated partial thromboplastin time (aPTT), and normal prothrombin time (PT).All 3 laboratory findings

    Other Noncancerous Hematologic Conditions with Known Genetic Association

    Testing is covered to establish or confirm a noncancerous hematologic condition with a known genetic association when clinical features are consistent with the disorder and testing will guide management.

    Qualifying clinical and management pathway

    • Examples of covered conditions: Atypical hemolytic-uremic syndrome; complete plasminogen activator inhibitor 1 deficiency; Diamond-Blackfan anemia; hereditary spherocytosis; Factor VII deficiency; Factor X deficiency; Factor XI deficiency (Hemophilia C); Factor XII deficiency; or Factor XIII deficiency.

    Selected Thalassemia Cases with Inconclusive Basic Testing

    Molecular analysis may be considered in selected cases when basic hematology and hemoglobin analysis cannot provide a conclusive diagnosis.

    Inconclusive prior evaluation: The member/enrollee has suspected thalassemia for which basic hematology and hemoglobin analysis cannot provide a conclusive diagnosis.

    Molecular analysis may also support genetic counseling, reproductive risk calculation in offspring, prediction of clinical severity, and clinical management.